ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2796

Elevated Serum Immunoglobulin G Is a Prognostic Factor for Progression of Interstitial Lung Disease in Primary Sjögren’s Syndrome

Eriko Ishioka1, Katsuya Suzuki2, Naoshi Nishina2, Hidekata Yasuoka3, Kunihiro Yamaoka2 and Tsutomu Takeuchi2, 1Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: immunoglobulin (IG) and interstitial lung disease, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Sjögren's Syndrome: Translational Insights into Sjögren's Syndrome

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Lung involvement is a systemic manifestation of primary Sjögren’s syndrome (pSS), however, the prevalence in pSS is various (9-75 %) and details are still unclear. In addition, interstitial lung disease (ILD) associated with pSS shows several radiographic patterns such as nonspecific interstitial pneumonia (NSIP) and usual interstitial pneumonia (UIP). Although UIP pattern is known as a prognostic determinant in idiopathic interstitial pneumonia, risk factors for progression of ILD in pSS has not been established.The aim of this study is to investigate clinical features of lung involvement in pSS and prognostic factors for exacerbation of pSS-ILD.

Methods: Total 300 consecutive patients with pSS diagnosed according to the 1999 revised Japanese criteria for the diagnosis of pSS, between January 2012 and September 2014 at our division were enrolled after exclusion of secondary SS. Clinico-radiolographic characteristics were retrospectively investigated and statistically analyzed. ILD progression was defined by exacerbation on chest computed tomography (CT) image or pulmonary function test. 

Results: To screen lung involvements, chest X-ray was underwent in 239 patients and chest CT was evaluated in 111 patients. Lung involvements were confirmed in 31.4%. Mean age was 68.5 years old. This included ILD (n=23, 9.6%), chronic airway lesion (n=11, 4.6 %), cystic lesion (n=3, 1.3 %), and malignant lymphoma (n=3, 1.3 %). Notably, the prevalence of smoking history (≥10 cigarettes per day, p=0.03), and elderly (≥65 years old, p<0.01) were higher in pSS with lung involvement than pSS without lung involvement. Radiological patterns of 23 pSS-ILD were followings: 17 for NSIP (73.9%), 5 for UIP (21.7%) and 1 OP (4.35%). 9 were progressive and 17 were stable during observation periods. Comparing ILD progressive group with stable group, serum immunoglobulin (Ig) G were significantly elevated (2263 +/- 479 vs 1726 +/- 519 mg/dl, p=0.02) and ESSDAI was higher (10.8 +/- 1.9 vs 6.1 +/- 1.3, p<0.01).There was no significant difference in the extent of reticular abnormality, ground glass attenuation, consolidation, and micronodules between two groups. On the other hand, UIP patterns having honeycombing were significantly higher in ILD-progressive group (p=0.04). Remarkably, serum IgG levels were significantly elevated in the progressive case with UIP pattern (p=0.02), but not with NSIP pattern.

Conclusion: This study demonstrated that serum IgG levels was elevated in progressive group in pSS-ILD and a prognostic factor particularly in pSS-ILD patients with UIP pattern. In the pSS patients with UIP pattern and serum IgG elevation, careful observation should be needed for appropriate management of ILD.


Disclosure: E. Ishioka, None; K. Suzuki, None; N. Nishina, None; H. Yasuoka, None; K. Yamaoka, Pfizer, Chugai Pharma, Mitsubishi-Tanabe Pharma, Takeda Industrial Pharma, GlaxoSmithKline, Nippon Shinyaku, Eli Lilly, Janssen Pharma, Eisai Pharma, Astellas Pharma and Actelion Pharmaceuticals., 8; T. Takeuchi, Astellas Pharma Inc, Bristol-Myers KK, Chugai Pharmaceutical Co, Ltd, Daiichi Sankyo Co, Ltd, Eisai Co, Ltd, Mitsubishi Tanabe Pharma Corp, Pfizer Japan, Santen Pharmaceutical Co, Ltd, Takeda Pharmaceutical Co, Ltd, Teijin Pharma Ltd, AbbVie GK, Asahi Kas, 2,AbbVie GK, Bristol-Myers KK, Chugai Pharmaceutical Co, Ltd, Eisai Co, Ltd, Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Corp, Pfizer Japan Inc, Takeda Pharmaceutical Co, Ltd, Astellas Pharma Inc, and Daiichi Sankyo Co, Ltd; and consultant fees from, 8.

To cite this abstract in AMA style:

Ishioka E, Suzuki K, Nishina N, Yasuoka H, Yamaoka K, Takeuchi T. Elevated Serum Immunoglobulin G Is a Prognostic Factor for Progression of Interstitial Lung Disease in Primary Sjögren’s Syndrome [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/elevated-serum-immunoglobulin-g-is-a-prognostic-factor-for-progression-of-interstitial-lung-disease-in-primary-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elevated-serum-immunoglobulin-g-is-a-prognostic-factor-for-progression-of-interstitial-lung-disease-in-primary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology